GIST (Gastrointestinal Stromal Tumor) clinical trials are ongoing at Moffitt Cancer Center, where scientists and clinicians are continually working to develop new and better ways to treat patients with gastrointestinal stromal tumors (GISTs). As more is being learned about the genetic changes that can lead to the formation of GISTs, treatments are being developed and refined to specifically target these changes. Through our robust clinical trial program, Moffitt’s GIST patients can be among the first to benefit from promising new therapies that aren’t yet available in other settings as researchers evaluate their effectiveness compared to the current standard of care.
It’s important to note that every GIST treatment, including the current “gold standard,” was once only available through a clinical trial. The GIST clinical trials available at Moffitt feature many exciting new treatment options, such as:
- Drugs that target the KIT protein, which stimulates the interstitial cells of Cajal that line the gastrointestinal tract to grow and divide
- Front-line drug combinations, which can be more effective than single-drug treatments
- Therapeutic options for patients with advanced GISTs that are resistant to tyrosine kinase inhibitors
As a National Center Institute-designated Comprehensive Cancer Center, Moffitt is vigorously committed to the power of research in discovering groundbreaking technologies and treatments that improve patient outcomes and quality of life. Through our dedicated Sarcoma Program and Gastrointestinal Oncology Program, our researchers spearhead GIST clinical trials that often prove to be game changers for current patients and can benefit future patients as well.
Patients who turn to Moffitt for GIST treatment can feel confident that they have access to the most advanced care possible, whether it’s through GIST clinical trials or other options. Using a bench-to-bedside approach, our oncologists incorporate the latest laboratory findings into each patient’s treatment plan.